The Best and Worst Dow Stocks

Page 24 of 29

6. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 98

Short Interest as of Apr 30, 2025: 0.87%

Johnson & Johnson manufactures, researches, develops, and sells different products in the healthcare field. The company operates in the MedTech and Innovative Medicine segments. JNJ announced a 4.8% raise in the quarterly dividend, demonstrating 63 years of consecutive growth.

The firm reported its latest quarter’s results on 15th April. It grew its revenue by 2.39% and non-GAAP EPS by 2.2% year-on-year, surpassing Wall Street analysts’ estimates. This was all thanks to strong sales growth in both of its segments. Sales growth was recorded at 5.9% in the US, along with global sales reaching $21.9 billion. Due to product mix changes and biosimilar competition, gross margin was affected.

Based on better-than-expected latest quarter earnings, the management guided for an optimistic 2025. As per the guidance, operational sales are anticipated to grow between 3.3% to 4.3%, including the Intra-Cellular acquisition. Aided by pipeline advancements and newly launched products, higher growth is expected in the second half of 2025. Adjusted EPS is projected to be in the range of $10.50 to $10.70.

Page 24 of 29